TriLink BioTechnologies, part of Maravai LifeSciences, Expands R&D Leadership Team
July 06 2022 - 4:05PM
TriLink BioTechnologies (TriLink), a Maravai LifeSciences company
(Maravai) (NASDAQ: MRVI) and a leader in the production of nucleic
acids for research, diagnostics and therapeutics applications,
today announced that Kate Broderick, Ph.D., has joined the Company
as Senior Vice President of Research and Development. In this newly
created role, Kate will have responsibility for leading TriLink’s
research and development strategy and scientific direction. She
will report to Michael Houston, Chief Scientific Officer.
“We are very excited that Kate has joined
TriLink and welcome her to the senior leadership team,” said Dr.
Houston. “Kate brings valuable experience to the role as we
continue to invest in our capabilities as a critical supplier of
modified nucleic acids and as a CDMO partner for customers from
early research through to clinical trials. Kate’s leadership role
in R&D will be pivotal in supporting the long-term growth of
the business.”
“Kate is a seasoned life sciences executive with
a proven track record of leadership, strategy development,
operational management and product development. She is an expert in
DNA technology and is uniquely qualified to lead TriLink’s R&D
initiatives,” Dr. Houston added.
Kate has extensive experience and expertise in
leading and liaising with multi-disciplinary groups from discovery
and R&D to engineering and clinical teams. She brings strong
and broad scientific expertise to TriLink, which covers multiple
areas, including gene delivery, medical devices, gene therapies for
the treatment of various infectious diseases, cancer
immunotherapies and vaccine development. Additionally, she has
extensive experience with non-viral delivery systems for a wide
range of vaccine targets and cancer immunotherapies. Kate has
published extensively and is a respected industry expert in the
areas of DNA delivery and DNA based technologies.
Prior to joining TriLink, Kate spent 15 years
with Inovio Pharmaceuticals where she assumed positions of
increasing responsibility, starting as Scientist, to her most
recent position as Senior Vice President, R&D. She received her
B.Sc. in Genetics and her Ph.D. in Molecular Genetics from the
University of Glasgow.
About TriLink
BioTechnologiesTriLink BioTechnologies, part of Maravai
LifeSciences, is a CDMO helping life science leaders and innovators
overcome challenges in the synthesis and scale-up of nucleic acids,
NTPs and mRNA capping analogs with scale-up expertise and unique
mRNA production capabilities, including its proprietary CleanCap®
mRNA capping technology. TriLink continues to expand its cGMP and
general manufacturing capacity at its new global headquarters to
support mRNA, oligonucleotide & plasmid therapeutic, vaccine
and diagnostic customers. For more information about TriLink, visit
www.trilinkbiotech.com.
About Maravai Maravai is a leading life
sciences company providing critical products to enable the
development of drug therapies, diagnostics, and novel vaccines and
to support research on human diseases. Maravai’s companies are
leaders in providing products and services in the fields of nucleic
acid synthesis and biologics safety testing to many of the world's
leading biopharmaceutical, vaccine, diagnostics, and cell and gene
therapies companies.
Contact Information:
Media Contact: Sara Michelmore
MacDougall
+1 781-235-3060
maravai@macdougall.bio
Investor Contact: Deb Hart
Maravai LifeSciences
+ 1 858-988-5917
ir@maravai.com
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From Apr 2023 to Apr 2024